These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8039471)

  • 1. Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action.
    Schmutz M; Brugger F; Gentsch C; McLean MJ; Olpe HR
    Epilepsia; 1994; 35 Suppl 5():S47-50. PubMed ID: 8039471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxcarbazepine: mechanisms of action.
    McLean MJ; Schmutz M; Wamil AW; Olpe HR; Portet C; Feldmann KF
    Epilepsia; 1994; 35 Suppl 3():S5-9. PubMed ID: 8156978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of oxcarbazepine and 10-hydroxycarbamazepine on action potential firing and generalized seizures.
    Wamil AW; Schmutz M; Portet C; Feldmann KF; McLean MJ
    Eur J Pharmacol; 1994 Dec; 271(2-3):301-8. PubMed ID: 7705430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticonvulsant action of oxcarbazepine, hydroxycarbamazepine, and carbamazepine against metrazol-induced motor seizures in developing rats.
    Kubová H; Mares P
    Epilepsia; 1993; 34(1):188-92. PubMed ID: 8422858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance.
    Baruzzi A; Albani F; Riva R
    Epilepsia; 1994; 35 Suppl 3():S14-9. PubMed ID: 8156974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxcarbazepine: clinical development program.
    Schwabe S
    Epilepsia; 1994; 35 Suppl 5():S51-3. PubMed ID: 8039472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticonvulsant and sodium channel blocking activity of higher doses of clenbuterol.
    Fischer W; Kittner H; Regenthal R; Malinowska B; Schlicker E
    Naunyn Schmiedebergs Arch Pharmacol; 2001 Feb; 363(2):182-92. PubMed ID: 11218071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacology and pharmacokinetics of oxcarbazepine.
    Lloyd P; Flesch G; Dieterle W
    Epilepsia; 1994; 35 Suppl 3():S10-3. PubMed ID: 8156973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions between oxcarbazepine and conventional antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis.
    Luszczki JJ; Borowicz KK; Swiader M; Czuczwar SJ
    Epilepsia; 2003 Apr; 44(4):489-99. PubMed ID: 12680997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticonvulsant profile and mechanism of action of propranolol and its two enantiomers.
    Fischer W
    Seizure; 2002 Jul; 11(5):285-302. PubMed ID: 12076101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticonvulsant profiles of the potent and orally active GABA uptake inhibitors SK&F 89976-A and SK&F 100330-A and four prototype antiepileptic drugs in mice and rats.
    Swinyard EA; White HS; Wolf HH; Bondinell WE
    Epilepsia; 1991; 32(4):569-77. PubMed ID: 1831122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs.
    White HS
    Epilepsia; 1999; 40 Suppl 5():S2-10. PubMed ID: 10530688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the anticonvulsant properties of F-721.
    Swinyard EA; Wolf HH; White HS; Skeen GA; Stark LG; Albertson T; Pong SF; Drust EG
    Epilepsy Res; 1993 May; 15(1):35-45. PubMed ID: 8391982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug.
    Isoherranen N; Woodhead JH; White HS; Bialer M
    Epilepsia; 2001 Jul; 42(7):831-6. PubMed ID: 11488880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetic variability of oxcarbazepine in epileptic patients].
    Viola MS; Bercellini MA; Saidón P; Rubio MC
    Medicina (B Aires); 2000; 60(6):914-8. PubMed ID: 11436701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticonvulsant profile of flunarizine and relation to Na(+) channel blocking effects.
    Fischer W; Kittner H; Regenthal R; De Sarro G
    Basic Clin Pharmacol Toxicol; 2004 Feb; 94(2):79-88. PubMed ID: 14748851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic and pharmacokinetic interaction studies of loreclezole with felbamate, lamotrigine, topiramate, and oxcarbazepine in the mouse maximal electroshock seizure model.
    Luszczki JJ; Ratnaraj N; Patsalos PN; Czuczwar SJ
    Epilepsia; 2005 Mar; 46(3):344-55. PubMed ID: 15730531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are neuronal nicotinic receptors a target for antiepileptic drug development? Studies in different seizure models in mice and rats.
    Löscher W; Potschka H; Wlaź P; Danysz W; Parsons CG
    Eur J Pharmacol; 2003 Apr; 466(1-2):99-111. PubMed ID: 12679146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor.
    Carter RB; Wood PL; Wieland S; Hawkinson JE; Belelli D; Lambert JJ; White HS; Wolf HH; Mirsadeghi S; Tahir SH; Bolger MB; Lan NC; Gee KW
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1284-95. PubMed ID: 9067315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticonvulsant and sodium channel blocking effects of ralitoline in different screening models.
    Fischer W; Bodewei R; Satzinger G
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Oct; 346(4):442-52. PubMed ID: 1331817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.